Incident at Baxter plant leaves 1 dead, 2 injured; Teva attacks Seroquel's Euro patent;

 @FiercePharma: Branded drugs to eke out 1.3% growth to 2015. Report | Follow @FiercePharma

> One employee has died and two have been injured after an incident at Baxter International's manufacturing facility in Atwater, California last weekend. News

> Teva Pharmaceutical Industries has launched a High Court action in London to revoke the European patent for AstraZeneca's atypical antipsychotics Seroquel, the Sunday Times reported. Article

> Clinical Data aims to compete in the lucrative antidepressant market with its newly approved drug Viibryd, which may not carry the same sexual side effects that plague some older drugs. FDA release | Report

> Biogen Idec said six patients taking its multiple sclerosis drug Tysabri developed a potentially fatal brain infection in December, bringing the total number of such cases associated with the drug to 85. Report

> Abbott Laboratories, Johnson & Johnson and Pfizer are among the first U.S. drugmakers to sign up for a new public/private sector partnership in healthcare agreed between China and the U.S. Story

> Europe's drive to cut drug prices coupled with U.S. healthcare reforms will weigh on global pharmaceutical companies' growth outlooks for 2011. Item    

> Teva Pharmaceutical Industries, the world's biggest generic drugmaker, has signed a new three-year, $1.5 billion unsecured revolving credit facility. News

Biotech News

 @FierceBiotech: Biotech VC investing grows 3% in 2010. Story | Follow @FierceBiotech

 @JohnCFierce: Merck KGaA's MS pill cladribine goes down for a second time in Europe. Can't reapply until '12. Article | Follow @JohnCFierce

> R&D chief Mackay puts his stamp on AZ pipeline plans. News

> "Frustrated" NIH chief plots $1B drug development effort. Article

> Clinical Data wins FDA OK for new antidepressant. Report 

> Scangos: "You have to be realistic about where we sit in the food chain." Item

Biotech IT News

> Continuous vitals monitoring on deck for ePRO. Story 

> CRO partner choices show analytics trend. News 

> H1N1 tweet study suggests tool for health officials. Article 

> Blue Chip probes social media use in recruitment. Item 

> SCOUT data to fuel FDA diet-pill/cardio model. Story 

> Nonprofits to standardize disease-specific trial records. News 

Medical Device News

> Industry, analysts react to 510(k) reform ideas. Report 

> St. Jude pays $16M to settle gov't probe. Story 

> Promising Cleveland Clinic spinoff goes on "hiatus." News 

> Med device VC investing falls 9% in 2010. Article 

> Boston Sci pays $375M for Atritech. Report 

> FDA could toughen regs for defibrillators. Item 

> FDA considers relaxing electroshock device regulation. Story

And Finally... Federal regulators are weighing whether to downgrade the risk classification of electroshock devices, reinforcing what many psychiatrists consider a deepening acceptance of electroshock in modern therapy. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.